It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is associated with risk of metachronous (non-simultaneous) contralateral breast cancer (CBC), and to what extent endocrine therapy affects this association.We studied the effect of ER-status of the first cancer on the risk of CBC overall, and for different ER-subtypes of CBC, using a large, population-based cohort. The cohort consisted of all women diagnosed with breast cancer in the Stockholm region 1976–2005; 25715 patients, of whom 940 suffered CBC. The relative risk was analyzed mainly using standardized incidence ratios (SIR).Women with breast cancer had a doubled risk of CBC compared to the risk of breast cancer in the general female population (SIR: 2....
BackgroundResults from randomized trials indicate that treatment with tamoxifen or chemotherapy for ...
Breast cancer risk is increased with current Menopausal Hormone Therapy (MHT) use, with higher risks...
A contralateral breast cancer (CBC) is today treated as an independent primary tumour, although rece...
It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is associated wit...
BACKGROUND: It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is as...
Abstract Background Previous population-based studies...
Compared with the breast cancer risk women in the general population have, breast cancer survivors h...
Abstract Several reproductive factors are known to be associated with risk of breast c...
breast cancer by approximately 30%–50%, with benefits probably limited to women with estrogen recept...
Background: An increasing number of breast cancer (BC) survivors are at risk of developing contralat...
Background An increasing number of breast cancer (BC) survivors are at risk of developing contralate...
A recent study reported an increased risk of contralateral estrogen-negative breast cancer after a f...
Introduction: Hormone receptor (HR) status has become an established target in treatment strategies ...
BackgroundRisk factors may differentially influence development of estrogen receptor (ER)-positive v...
Of the nearly 185 000 US women who were expected to develop breast cancer in 2009 and the more than ...
BackgroundResults from randomized trials indicate that treatment with tamoxifen or chemotherapy for ...
Breast cancer risk is increased with current Menopausal Hormone Therapy (MHT) use, with higher risks...
A contralateral breast cancer (CBC) is today treated as an independent primary tumour, although rece...
It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is associated wit...
BACKGROUND: It is unclear whether estrogen receptor (ER)-status of first primary breast cancer is as...
Abstract Background Previous population-based studies...
Compared with the breast cancer risk women in the general population have, breast cancer survivors h...
Abstract Several reproductive factors are known to be associated with risk of breast c...
breast cancer by approximately 30%–50%, with benefits probably limited to women with estrogen recept...
Background: An increasing number of breast cancer (BC) survivors are at risk of developing contralat...
Background An increasing number of breast cancer (BC) survivors are at risk of developing contralate...
A recent study reported an increased risk of contralateral estrogen-negative breast cancer after a f...
Introduction: Hormone receptor (HR) status has become an established target in treatment strategies ...
BackgroundRisk factors may differentially influence development of estrogen receptor (ER)-positive v...
Of the nearly 185 000 US women who were expected to develop breast cancer in 2009 and the more than ...
BackgroundResults from randomized trials indicate that treatment with tamoxifen or chemotherapy for ...
Breast cancer risk is increased with current Menopausal Hormone Therapy (MHT) use, with higher risks...
A contralateral breast cancer (CBC) is today treated as an independent primary tumour, although rece...